Starling Oncology, Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
Starling Oncology, Inc. (STLN) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $2.71 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $2.71M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $2.71M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $2.84M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $2.84M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-06-30 | $2.71M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.71M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.84M 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.84M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $2.83M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $3.06M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $3.09M 10-K · filed 2025-03-26 |
| 2024-09-30 | $3.09M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $3.09M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $3.09M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $3.08M 10-K · filed 2024-03-28 |
| 2023-09-30 | $3.08M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $3.08M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $2.91M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $2.91M 10-K · filed 2023-03-16 |
| 2022-09-30 | $732.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.47M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $2.01M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $2.68M 10-K · filed 2022-03-11 |